ada standards of care 2025 glp-1 receptor agonists recommendations The New ADA/EASD Type 1 Diabetes Adult Guidelines Your Guide to the 2025

Neurodegenerative diseases, including Alzheimers Disease (AD) and Parkinsons Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system

While these agents are not recommended during pregnancy, their use in the preconception, periconception, and postpartum periods is increasing

There is no argument that the drugs are much more potent and faster acting than your bodies natural GLP-1 hormones

CONTRIBUTED BY REAL CHEMISTRY | BY RITA GLAZE-ROWE ALABAMA A new study on behalf of Real Chemistry has identified which state Medicaid programs cover GLP-1s.The growing popularity of GLP-1 receptor agonists including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly has added fuel to an already fiery []

Since most glucose-dependent insulinotropic polypeptide (GIP) receptor: glucagon-like peptide- 1 receptor (GLP- 1) receptor: glucagon receptor triagonists compete in efficacy with bariatric surgery, the success of these agents in preclinical models and clinical trials suggests a bright future for multi-agonists in the treatment of metabolic diseases